CAMBRIDGE, Mass., Sept. 28, 2012 /PRNewswire/ -- Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming conferences.
"With a focused approach on personalized therapeutics for genetically defined cancers, Epizyme is excited to present the foundations of our clinical platform and share this information with both the scientific community and investors," said Jason Rhodes, Executive Vice President and Chief Business Officer, Epizyme.
Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a family of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.
Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). For more information, visit www.epizyme.com.
202.955.6222 x 2597
SOURCE Epizyme, Inc.